What the Study Found (In Plain English)
Published in Clinical and translational science (2026), this phase iii randomized trial evaluating human clinical outcomes investigated: Phase 2a trials in tuberculosis patients traditionally assess early bactericidal activity over two weeks, often using the time-to-positivity biomarker, followed by a phase 2b study typically lasting 8-week with time-to-event of culture conversion as the endpoint. Key clinical takeaway: Four-week time-to-positivity phase 2a data provided more information compared to the 2-week time-to-positivity data for the prediction of culture conversion.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Clinical and translational science, 2026-08-15; Phase III Randomized Trial; Rigor 82/100): Four-week time-to-positivity phase 2a data provided more information compared to the 2-week time-to-positivity data for the prediction of culture conversion.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.